BCL6 and cancer: We found that tumor cases with lower levels of Bcl6 mRNA had favorable overall survival rates in all types of cancer (Fig S1A) and this phenotype was confirmed in colon adenocarcinoma (COAD, with P = 0.049), pancreatic adenocarcinoma (PAAD, with P = 0.021), and, possibly, rectum adenocarcinoma (READ, no significant difference but trend was shown) (Fig S1B–D).